Our Diabetic Range
Our comprehensive diabetes range is designed to provide effective glycemic control with innovative formulations that address insulin resistance, glucose regulation, and overall metabolic health. From powerful monotherapies to synergistic combination therapies, our products help manage Type 2 Diabetes Mellitus with improved insulin sensitivity, reduced glucose production, and better postprandial control. With a focus on safety, efficacy, and patient convenience, our range includes DPP-4 inhibitors, biguanides, sulfonylureas, and combination therapies, ensuring optimal diabetes management for various patient needs.
METGLYCO-1
METGLYCO-1 (Metformin Hydrochloride 500 mg Prolonged-release + Glimepiride 1 mg Tablets IP)
A dual-action therapy for Type 2 Diabetes Mellitus, reducing fasting and postprandial glucose while improving insulin sensitivity. Metformin controls glucose production, and Glimepiride enhances insulin secretion, ensuring better glycemic control with a lower risk of hypoglycemia.
Also available:
METGLYCO 2 (Metformin Hydrochloride 500 mg Prolonged-release + Glimepiride 2 mg Tablets IP) for patients requiring higher Glimepiride dosage.
METGLYCO-2
METGLYCO-1 (Metformin Hydrochloride 500 mg Prolonged-release + Glimepiride 1 mg Tablets IP)
A dual-action therapy for Type 2 Diabetes Mellitus, reducing fasting and postprandial glucose while improving insulin sensitivity. Metformin controls glucose production, and Glimepiride enhances insulin secretion, ensuring better glycemic control with a lower risk of hypoglycemia.
Also available:
METGLYCO 2 (Metformin Hydrochloride 500 mg Prolonged-release + Glimepiride 2 mg Tablets IP) for patients requiring higher Glimepiride dosage.
METGLYCO-V
METGLYCO-V (Vildagliptin 50 mg + Metformin Hydrochloride 500 mg SR Tablets IP)
A dual-action therapy for Type 2 Diabetes Mellitus, combining Vildagliptin, a DPP-4 inhibitor that stimulates insulin release and controls blood sugar spikes, with Metformin, which enhances insulin sensitivity and reduces glucose production. This combination ensures better glycemic control with improved tolerance and minimal risk of hypoglycemia.
Also available:
METGLYCO 2 (Metformin Hydrochloride 500 mg Prolonged-release + Glimepiride 2 mg Tablets IP) for patients needing additional insulin stimulation.
CareDapa-10
CareDapa-10 (Dapagliflozin Tablets IP 10 mg)
A highly effective SGLT2 inhibitor that lowers both basal and postprandial plasma glucose by reducing glucose reabsorption in the kidneys. With proven cardiovascular benefits, it is approved as monotherapy for metformin-intolerant patients or as a combination therapy in Type 2 Diabetes Mellitus. CareDapa-10 ensures better glycemic control with a low risk of hypoglycemia, making it ideal for diabetic patients with cardiovascular conditions.